DNA methylome profiling beyond promoters - Taking an epigenetic snapshot of the breast tumor microenvironment

FEBS Journal

Volumn 282, Issue 9, 2015, Pages 1801-1814

  Jeschke, Jana ^a   Collignon, Evelyne ^a   Fuks, François ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Breast cancer; Cell frequency; Cell identity; Cell lineage specificity; Clinical outcome; DNA methylation; Prognosis; Tumor immune response; Tumor microenvironment; Tumor infiltrating lymphocytes

Indexed keywords

DNA; ESTROGEN RECEPTOR; HISTONE H3; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN MLH1; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER PROGNOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LINEAGE; CELL SPECIFICITY; CPG ISLAND; DNA METHYLATION; DNA METHYLATION PROFILING; EPIGENETICS; FOXP3 GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC PROCEDURES; HUMAN; PRIORITY JOURNAL; PROMOTER REGION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; BREAST TUMOR; FEMALE; GENETIC EPIGENESIS; GENETICS; PATHOLOGY;

BREAST NEOPLASMS; CELL LINEAGE; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; HUMANS; TUMOR MICROENVIRONMENT;

EID: 84928530388     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13125     Document Type: Article

References (108)

1. Shen H, &, Laird PW, (2013) Interplay between the cancer genome and epigenome. Cell 153, 38-55.
2. Dawson MA, &, Kouzarides T, (2012) Cancer epigenetics: from mechanism to therapy. Cell 150, 12-27.
3. Denis H, Ndlovu MN, &, Fuks F, (2011) Regulation of mammalian DNA methyltransferases: a route to new mechanisms. EMBO Rep 12, 647-656.
4. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, Nery JR, Lee L, Ye Z, Ngo QM, et al.,. (2009) Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462, 315-322.
5. Ross JP, Rand KN, &, Molloy PL, (2010) Hypomethylation of repeated DNA sequences in cancer. Epigenomics 2, 245-269.
6. Konkel MK, &, Batzer MA, (2010) A mobile threat to genome stability: the impact of non-LTR retrotransposons upon the human genome. Semin Cancer Biol 20, 211-221.
7. Koester B, Rea TJ, Templeton AR, Szalay AS, &, Sing CF, (2012) Long-range autocorrelations of CpG islands in the human genome. PLoS One 7, e29889.
8. Ginno PA, Lim YW, Lott PL, Korf I, &, Chedin F, (2013) GC skew at the 5′ and 3′ ends of human genes links R-loop formation to epigenetic regulation and transcription termination. Genome Res 23, 1590-1600.
9. Vinson C, &, Chatterjee R, (2012) CG methylation. Epigenomics 4, 655-663.
10. Deaton AM, &, Bird A, (2011) CpG islands and the regulation of transcription. Genes Dev 25, 1010-1022.
11. Baylin SB, &, Jones PA, (2011) A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 11, 726-734.
12. Quail DF, &, Joyce JA, (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19, 1423-1437.
13. Junttila MR, &, de Sauvage FJ, (2013) Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501, 346-354.
14. Ndlovu MN, Denis H, &, Fuks F, (2011) Exposing the DNA methylome iceberg. Trends Biochem Sci 36, 381-387.
15. Shenker N, &, Flanagan JM, (2012) Intragenic DNA methylation: implications of this epigenetic mechanism for cancer research. Br J Cancer 106, 248-253.
16. Reddington JP, Pennings S, &, Meehan RR, (2013) Non-canonical functions of the DNA methylome in gene regulation. Biochem J 451, 13-23.
17. Hunt BG, Glastad KM, Yi SV, &, Goodisman MA, (2013) The function of intragenic DNA methylation: insights from insect epigenomes. Integr Comp Biol 53, 319-328.
18. Kulis M, Queiros AC, Beekman R, &, Martin-Subero JI, (2013) Intragenic DNA methylation in transcriptional regulation, normal differentiation and cancer. Biochim Biophys Acta 1829, 1161-1174.
19. Thomas RM, Sai H, &, Wells AD, (2012) Conserved intergenic elements and DNA methylation cooperate to regulate transcription at the il17 locus. J Biol Chem 287, 25049-25059.
20. Lu L, Zhu G, Zhang C, Deng Q, Katsaros D, Mayne ST, Risch HA, Mu L, Canuto EM, Gregori G, et al.,. (2012) Association of large noncoding RNA HOTAIR expression and its downstream intergenic CpG island methylation with survival in breast cancer. Breast Cancer Res Treat 136, 875-883.
21. Schlesinger F, Smith AD, Gingeras TR, Hannon GJ, &, Hodges E, (2013) De novo DNA demethylation and noncoding transcription define active intergenic regulatory elements. Genome Res 23, 1601-1614.
22. Delpu Y, Cordelier P, Cho WC, &, Torrisani J, (2013) DNA methylation and cancer diagnosis. Int J Mol Sci 14, 15029-15058.
23. Clark C, Palta P, Joyce CJ, Scott C, Grundberg E, Deloukas P, Palotie A, &, Coffey AJ, (2012) A comparison of the whole genome approach of MeDIP-seq to the targeted approach of the Infinium HumanMethylation450 BeadChip((R)) for methylome profiling. PLoS One 7, e50233.
24. Meissner A, Gnirke A, Bell GW, Ramsahoye B, Lander ES, &, Jaenisch R, (2005) Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res 33, 5868-5877.
25. Gu H, Smith ZD, Bock C, Boyle P, Gnirke A, &, Meissner A, (2011) Preparation of reduced representation bisulfite sequencing libraries for genome-scale DNA methylation profiling. Nat Protoc 6, 468-481.
26. Doherty R, &, Couldrey C, (2014) Exploring genome wide bisulfite sequencing for DNA methylation analysis in livestock: a technical assessment. Front Genet 5, 126.
27. Dedeurwaerder S, Defrance M, Calonne E, Denis H, Sotiriou C, &, Fuks F, (2011) Evaluation of the Infinium Methylation 450K technology. Epigenomics 3, 771-784.
28. Novak P, Jensen T, Oshiro MM, Watts GS, Kim CJ, &, Futscher BW, (2008) Agglomerative epigenetic aberrations are a common event in human breast cancer. Cancer Res 68, 8616-8625.
29. van Hoesel AQ, van de Velde CJ, Kuppen PJ, Liefers GJ, Putter H, Sato Y, Elashoff DA, Turner RR, Shamonki JM, de Kruijf EM, et al.,. (2012) Hypomethylation of LINE-1 in primary tumor has poor prognosis in young breast cancer patients: a retrospective cohort study. Breast Cancer Res Treat 134, 1103-1114.
30. Costa FF, Paixao VA, Cavalher FP, Ribeiro KB, Cunha IW, Rinck JA Jr, O'Hare M, Mackay A, Soares FA, Brentani RR, et al.,. (2006) SATR-1 hypomethylation is a common and early event in breast cancer. Cancer Genet Cytogenet 165, 135-143.
31. Ito Y, Koessler T, Ibrahim AE, Rai S, Vowler SL, Abu-Amero S, Silva AL, Maia AT, Huddleston JE, Uribe-Lewis S, et al.,. (2008) Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer. Hum Mol Genet 17, 2633-2643.
32. Sharma G, Mirza S, Parshad R, Srivastava A, Datta Gupta S, Pandya P, &, Ralhan R, (2010) CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients. Clin Biochem 43, 373-379.
33. Pakneshan P, Szyf M, &, Rabbani SA, (2005) Hypomethylation of urokinase (uPA) promoter in breast and prostate cancer: prognostic and therapeutic implications. Curr Cancer Drug Targets 5, 471-488.
34. Paredes J, Albergaria A, Oliveira JT, Jeronimo C, Milanezi F, &, Schmitt FC, (2005) P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res 11, 5869-5877.
35. Shann YJ, Cheng C, Chiao CH, Chen DT, Li PH, &, Hsu MT, (2008) Genome-wide mapping and characterization of hypomethylated sites in human tissues and breast cancer cell lines. Genome Res 18, 791-801.
36. Wang L, Tang L, Xie R, Nie W, Chen L, &, Guan X, (2012) p16 promoter hypermethylation is associated with increased breast cancer risk. Mol Med Rep 6, 904-908.
37. Fumagalli C, Pruneri G, Possanzini P, Manzotti M, Barile M, Feroce I, Colleoni M, Bonanni B, Maisonneuve P, Radice P, et al.,. (2012) Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients. Breast Cancer Res Treat 134, 131-137.
38. Murata H, Khattar NH, Gu L, &, Li GM, (2005) Roles of mismatch repair proteins hMSH2 and hMLH1 in the development of sporadic breast cancer. Cancer Lett 223, 143-150.
39. Park SY, Kwon HJ, Lee HE, Ryu HS, Kim SW, Kim JH, Kim IA, Jung N, Cho NY, &, Kang GH, (2011) Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch 458, 73-84.
40. Shetty PJ, Pasupuleti N, Chava S, Nasaruddin K, &, Hasan Q, (2011) Altered transcription and expression of PTEN in breast tumors: is it regulated by hypermethylation? Breast Dis 33, 27-33.
41. Shetty PJ, Movva S, Pasupuleti N, Vedicherlla B, Vattam KK, Venkatasubramanian S, Ahuja YR, &, Hasan Q, (2011) Regulation of IGF2 transcript and protein expression by altered methylation in breast cancer. J Cancer Res Clin Oncol 137, 339-345.
42. Swift-Scanlan T, Smith CT, Bardowell SA, &, Boettiger CA, (2014) Comprehensive interrogation of CpG island methylation in the gene encoding COMT, a key estrogen and catecholamine regulator. BMC Med Genomics 7, 5.
43. Stone A, Cowley MJ, Valdes-Mora F, McCloy RA, Sergio CM, Gallego-Ortega D, Caldon CE, Ormandy CJ, Biankin AV, Gee JM, et al.,. (2013) BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer. Mol Cancer Ther 12, 1874-1885.
44. Hill VK, Ricketts C, Bieche I, Vacher S, Gentle D, Lewis C, Maher ER, &, Latif F, (2011) Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res 71, 2988-2999.
45. Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jonsson G, Olsson H, Borg A, &, Ringner M, (2010) Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res 12, R36.
46. Fackler MJ, Umbricht CB, Williams D, Argani P, Cruz LA, Merino VF, Teo WW, Zhang Z, Huang P, Visvananthan K, et al.,. (2011) Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res 71, 6195-6207.
47. Kamalakaran S, Varadan V, Giercksky Russnes HE, Levy D, Kendall J, Janevski A, Riggs M, Banerjee N, Synnestvedt M, Schlichting E, et al.,. (2011) DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables. Mol Oncol 5, 77-92.
48. Ambrosone CB, Young AC, Sucheston LE, Wang D, Yan L, Liu S, Tang L, Hu Q, Freudenheim JL, Shields PG, et al.,. (2014) Genome-wide methylation patterns provide insight into differences in breast tumor biology between American women of African and European ancestry. Oncotarget 5, 237-248.
49. Ronneberg JA, Fleischer T, Solvang HK, Nordgard SH, Edvardsen H, Potapenko I, Nebdal D, Daviaud C, Gut I, Bukholm I, et al.,. (2011) Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Mol Oncol 5, 61-76.
50. Bediaga NG, Acha-Sagredo A, Guerra I, Viguri A, Albaina C, Ruiz Diaz I, Rezola R, Alberdi MJ, Dopazo J, Montaner D, et al.,. (2010) DNA methylation epigenotypes in breast cancer molecular subtypes. Breast Cancer Res 12, R77.
51. Dedeurwaerder S, Desmedt C, Calonne E, Singhal SK, Haibe-Kains B, Defrance M, Michiels S, Volkmar M, Deplus R, Luciani J, et al.,. (2011) DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Mol Med 3, 726-741.
52. Cornen S, Guille A, Adelaide J, Addou-Klouche L, Finetti P, Saade MR, Manai M, Carbuccia N, Bekhouche I, Letessier A, et al.,. (2014) Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling. PLoS One 9, e81843.
53. Cancer Genome Atlas N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70.
54. Day TK, &, Bianco-Miotto T, (2013) Common gene pathways and families altered by DNA methylation in breast and prostate cancers. Endocr Relat Cancer 20, R215-R232.
55. Sorensen AL, Timoskainen S, West FD, Vekterud K, Boquest AC, Ahrlund-Richter L, Stice SL, &, Collas P, (2010) Lineage-specific promoter DNA methylation patterns segregate adult progenitor cell types. Stem Cells Dev 19, 1257-1266.
56. Berdasco M, &, Esteller M, (2011) DNA methylation in stem cell renewal and multipotency. Stem Cell Res Ther 2, 42.
57. Smith ZD, &, Meissner A, (2013) DNA methylation: roles in mammalian development. Nat Rev Genet 14, 204-220.
58. Yeo S, Jeong S, Kim J, Han JS, Han YM, &, Kang YK, (2007) Characterization of DNA methylation change in stem cell marker genes during differentiation of human embryonic stem cells. Biochem Biophys Res Commun 359, 536-542.
59. Maunakea AK, Nagarajan RP, Bilenky M, Ballinger TJ, D'Souza C, Fouse SD, Johnson BE, Hong C, Nielsen C, Zhao Y, et al.,. (2010) Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 466, 253-257.
60. Deaton AM, Webb S, Kerr AR, Illingworth RS, Guy J, Andrews R, &, Bird A, (2011) Cell type-specific DNA methylation at intragenic CpG islands in the immune system. Genome Res 21, 1074-1086.
61. Maunakea AK, Chepelev I, Cui K, &, Zhao K, (2013) Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition. Cell Res 23, 1256-1269.
62. Bloushtain-Qimron N, Yao J, Snyder EL, Shipitsin M, Campbell LL, Mani SA, Hu M, Chen H, Ustyansky V, Antosiewicz JE, et al.,. (2008) Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci USA 105, 14076-14081.
63. Maruyama R, Choudhury S, Kowalczyk A, Bessarabova M, Beresford-Smith B, Conway T, Kaspi A, Wu Z, Nikolskaya T, Merino VF, et al.,. (2011) Epigenetic regulation of cell type-specific expression patterns in the human mammary epithelium. PLoS Genet 7, e1001369.
64. Novak P, Stampfer MR, Munoz-Rodriguez JL, Garbe JC, Ehrich M, Futscher BW, &, Jensen TJ, (2012) Cell-type specific DNA methylation patterns define human breast cellular identity. PLoS One 7, e52299.
65. Fridman WH, Pages F, Sautes-Fridman C, &, Galon J, (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12, 298-306.
66. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, &, Karin M, (2010) B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464, 302-305.
67. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, &, Syrjanen K, (1992) Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 28A, 859-864.
68. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, et al.,. (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28, 105-113.
69. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, et al.,. (2013) Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31, 860-867.
70. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, &, Green AR, (2011) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29, 1949-1955.
71. Lanca T, &, Silva-Santos B, (2012) The split nature of tumor-infiltrating leukocytes: implications for cancer surveillance and immunotherapy. Oncoimmunology 1, 717-725.
72. Bos PD, &, Rudensky AY, (2012) Treg cells in cancer: a case of multiple personality disorder. Sci Transl Med 4, 164 fs44.
73. Whiteside TL, (2012) What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol 22, 327-334.
74. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, Lehr HA, Hengstler JG, Kolbl H, &, Gehrmann M, (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68, 5405-5413.
75. Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, Boehm D, Gebhard S, Petry I, Lebrecht A, et al.,. (2012) A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 18, 2695-2703.
76. de Visser KE, Korets LV, &, Coussens LM, (2005) De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7, 411-423.
77. Nelson BH, (2010) CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol 185, 4977-4982.
78. Mantovani A, &, Sica A, (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22, 231-237.
79. Biswas SK, &, Mantovani A, (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11, 889-896.
80. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, et al.,. (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1, 54-67.
81. Kalluri R, &, Zeisberg M, (2006) Fibroblasts in cancer. Nat Rev Cancer 6, 392-401.
82. Ostman A, &, Augsten M, (2009) Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr Opin Genet Dev 19, 67-73.
83. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, &, Weinberg RA, (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348.
84. Yamashita M, Ogawa T, Zhang X, Hanamura N, Kashikura Y, Takamura M, Yoneda M, &, Shiraishi T, (2012) Role of stromal myofibroblasts in invasive breast cancer: stromal expression of alpha-smooth muscle actin correlates with worse clinical outcome. Breast Cancer 19, 170-176.
85. Loeffler M, Kruger JA, Niethammer AG, &, Reisfeld RA, (2006) Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 116, 1955-1962.
86. Shekhar MP, Santner S, Carolin KA, &, Tait L, (2007) Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity. Am J Pathol 170, 1546-1560.
87. Pontiggia O, Sampayo R, Raffo D, Motter A, Xu R, Bissell MJ, Joffe EB, &, Simian M, (2012) The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through beta1 integrin. Breast Cancer Res Treat 133, 459-471.
88. Calle EE, &, Kaaks R, (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4, 579-591.
89. Bochet L, Meulle A, Imbert S, Salles B, Valet P, &, Muller C, (2011) Cancer-associated adipocytes promotes breast tumor radioresistance. Biochem Biophys Res Commun 411, 102-106.
90. Huh JI, Calvo A, Stafford J, Cheung M, Kumar R, Philp D, Kleinman HK, &, Green JE, (2005) Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms. Oncogene 24, 790-800.
91. Tchou J, &, Conejo-Garcia J, (2012) Targeting the tumor stroma as a novel treatment strategy for breast cancer: shifting from the neoplastic cell-centric to a stroma-centric paradigm. Adv Pharmacol 65, 45-61.
92. Chua W, Charles KA, Baracos VE, &, Clarke SJ, (2011) Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 104, 1288-1295.
93. Taylor CR, &, Levenson RM, (2006) Quantification of immunohistochemistry-issues concerning methods, utility and semiquantitative assessment II. Histopathology 49, 411-424.
94. Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, &, Gillanders WE, (2013) The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 139, 667-676.
95. Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, et al.,. (2013) CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 123, 2873-2892.
96. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, &, Caldas C, (2007) An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 8, R157.
97. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, et al.,. (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14, 518-527.
98. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, &, Sotiriou C, (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14, 5158-5165.
99. West NR, Milne K, Truong PT, Macpherson N, Nelson BH, &, Watson PH, (2011) Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 13, R126.
100. Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, Wiencke JK, &, Kelsey KT, (2012) DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics 13, 86.
101. Baron U, Turbachova I, Hellwag A, Eckhardt F, Berlin K, Hoffmuller U, Gardina P, &, Olek S, (2006) DNA methylation analysis as a tool for cell typing. Epigenetics 1, 55-60.
102. Baron U, Floess S, Wieczorek G, Baumann K, Grutzkau A, Dong J, Thiel A, Boeld TJ, Hoffmann P, Edinger M, et al.,. (2007) DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol 37, 2378-2389.
103. Wieczorek G, Asemissen A, Model F, Turbachova I, Floess S, Liebenberg V, Baron U, Stauch D, Kotsch K, Pratschke J, et al.,. (2009) Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res 69, 599-608.
104. Sehouli J, Loddenkemper C, Cornu T, Schwachula T, Hoffmuller U, Grutzkau A, Lohneis P, Dickhaus T, Grone J, Kruschewski M, et al.,. (2011) Epigenetic quantification of tumor-infiltrating T-lymphocytes. Epigenetics 6, 236-246.
105. Lucas S, van Baren N, de Smet C, &, Coulie PG, (2012) Demethylation of the FOXP3 gene in human melanoma cells precludes the use of this epigenetic mark for quantification of Tregs in unseparated melanoma samples. Int J Cancer 130, 1960-1966.
106. Koestler DC, Christensen B, Karagas MR, Marsit CJ, Langevin SM, Kelsey KT, Wiencke JK, &, Houseman EA, (2013) Blood-based profiles of DNA methylation predict the underlying distribution of cell types: a validation analysis. Epigenetics 8, 816-826.
107. Accomando WP, Wiencke JK, Houseman EA, Nelson HH, &, Kelsey KT, (2014) Quantitative reconstruction of leukocyte subsets using DNA methylation. Genome Biol 15, R50.
108. Reinius LE, Acevedo N, Joerink M, Pershagen G, Dahlen SE, Greco D, Soderhall C, Scheynius A, &, Kere J, (2012) Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility. PLoS One 7, e41361.